Ratings GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 05:48:40 2024-12-10 EST			5-day change	1st Jan Change
1,388.75 ^GBX	+0.42%		+1.41%	-4.34%

11:02am	RBC raises Hikma; JPMorgan cuts Schroders	AN
10:24am	GSK, Relation Therapeutics Partner to Develop Fibrotic Diseases, Osteoarthritis Treatment	MT

Summary: GSK plc

From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Highlights: GSK plc

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's high margin levels account for strong profits.
This company will be of major interest to investors in search of a high dividend stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Historically, the company has been releasing figures that are above expectations.

Weaknesses: GSK plc

In relation to the value of its tangible assets, the company's valuation appears relatively high.
Revenue estimates are regularly revised downwards for the current and coming years.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings Chart: GSK plc

Source: Surperformance

ESG chart: GSK plc

Source: Refinitiv

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Fundamentals	Composite Valuation	Composite Momentum	Capi. ($)
	GSK PLC				72.17B
	ELI LILLY AND COMPANY				724B
	NOVO NORDISK A/S				491B
	JOHNSON & JOHNSON				360B
	ABBVIE INC.				312B
	MERCK & CO., INC.				263B
	ROCHE HOLDING AG				236B
	ASTRAZENECA PLC				212B
	NOVARTIS AG				204B
	AMGEN INC.				149B
	Average				302.24B
	Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes